14 results about "Neointimal hyperplasia" patented technology

Devices and methods can be used to treat heart conditions, hypertension, and other medical disorders. For example, devices and methods for treating atrial fibrillation by performing thoracic vein ablation procedures, including pulmonary vein myocardium ablation are described herein. In some embodiments, the ablation is performed in coordination with the delivery a pharmacological agent that can abate the formation of tissue stenosis or neointimal hyperplasia caused by the ablation.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

The disclosure relates to compositions and methods for reducing SMAD3 expression in a blood vessel in a patient in need thereof. Also provided herein are compositions and methods for reducing blood vessel graft stenosis in a subject, preventing occlusion of a blood vessel or a blood vessel graft, reducing neointimal hyperplasia in a blood vessel or a blood vessel graft, increasing endothelization in a blood vessel or a blood vessel graft, increasing patency in a blood vessel or a blood vessel graft, reducing endothelial to mesenchymal transition (EndMT) in a blood vessel or a blood vessel graft, reducing thrombosis in in a blood vessel or a blood vessel graft and / or reducing TGF-beta signaling in a blood vessel or a blood vessel graft. In embodiments, the patient is undergoing arterio-venous fistula (AVF) surgery.

To provide a heterocyclic compound and its use.SOLUTION: Provided herein are novel heterocyclic compounds, e.g., compounds having Formula I, I-P, II, II-P, III, or IV. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in the inhibition of aldehyde dehydrogenase, retinoid pathway activation, and / or to treat various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH), or neointimal hyperplasia (NIH), or as a male contraceptive.SELECTED DRAWING: Figure 1A

The invention discloses application of nuclear receptor binding protein 2 in treatment of postoperative restenosis neointimal hyperplasia. The overexpressed nuclear receptor binding protein 2 can inhibit phenotypic transformation of vascular smooth muscle cells caused by platelet-derived growth factors (PDGF-BB) and enhancement of proliferation and migration capabilities. In addition, mouse carotid artery neointimal hyperplasia caused by carotid artery guide wire injury can be effectively improved through specific overexpression of the nuclear receptor binding protein 2 through smooth muscle cells, and it is prompted that the nuclear receptor binding protein 2 has a treatment effect and can serve as a marker to be applied to screening of drugs for treating postoperative restenosis neointimal hyperplasia.

The invention relates to application of lindelactone in preparation of a medicine for inhibiting neointimal hyperplasia in blood vessels. Based on the natural source and biological activity of the lindelactone, the invention develops a pharmaceutical molecule with application prospects, and the lindelactone can be used for preventing and / or treating endometrial neogenesis, and is especially suitable for intervention of interventional postoperative restenosis. The linderane is used for preventing neointimal neogenesis by inhibiting abnormal proliferation and migration of vascular smooth muscle cells. Experimental data show that lindelactone does not show obvious systemic toxicity under the treatment dosage and has lower potential of side effects. The lindelinolide provides parameter data for preparation of the medicine for inhibiting endovascular neointimal hyperplasia, is expected to be applied to percutaneous coronary intervention postoperative complications, especially prevention and treatment of stent restenosis, and can become a potential medicine for intervening in restenosis.

Devices and methods can be used to treat of heart conditions, hypertension, and other medical disorders. For example, devices and methods for treating atrial fibrillation by performing thoracic vein ablation procedures, including pulmonary vein myocardium ablation are described herein. In some embodiments, the ablation is performed in coordination with the delivery a pharmacological agent that can abate the formation of tissue stenosis or neointimal hyperplasia caused by the ablation.

The application relates to the technical field of medical devices, in particular to a spring stent, a stent catheter system and a stent implantation method. The spring stent provided by the application comprises a clockwork spring, the clockwork spring comprises a hollow cylinder which is spirally wound by a memory alloy wire mesh ring, the memory alloy wire mesh is kept flush at both ends of the hollow cylinder, and the side wall of the clockwork spring is a hollow structure. The spring stent can realize self-expansion and expansion in a blood vessel, effectively adhere to the inner wall of the blood vessel, and can elastically deform according to the memory elasticity to follow the contraction and expansion of the blood vessel, so that a good adhesion effect is achieved. In combination with a pushing assembly included in a stent delivery system and a cutting assembly connected to the distal end of the pushing assembly, the diseased part in the blood vessel can be cut during the implantation of the stent, so that the reliability of the stent adhesion is enhanced, and the risk of new thrombosis and neointimal hyperplasia is reduced.

The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).

The present application relates to an intravascular stent and a preparation method therefore. The intravascular stent includes: a stent body, developing fasteners, and developing members. The developing fasteners are arranged at the proximal and distal ends of the stent body, and each developing member is fixedly connected to a corresponding developing fastener in a one-to-one manner. Each developing member is fixed on the side of the corresponding developing fastener that is closer to the central axis of the stent body. In the intravascular stent described above, since the developing member is fixed on the side of the developing fastener closer to the central axis of the stent body, it can prevent the developing member from scraping against the inner wall of the microcatheter during delivery, thereby reducing the pushing force required for the intravascular stent and lowering clinical risks. Furthermore, once the intravascular stent is released, it can also prevent the developing member from irritating the inner wall of the blood vessel, thus reducing the risk of thrombosis and neointimal hyperplasia.

The present invention discloses an application of a histone methyltransferase SMYD2 in the preparation of a drug for preventing and treating restenosis caused by intimal regeneration after vascular injury. The prevention and treatment of restenosis caused by intimal regeneration after vascular injury is achieved by reducing the expression and activity of the histone methyltransferase SMYD2 in cells or tissues. By reducing the expression and activity of the histone methyltransferase SMYD2 in cells or tissues, the proliferation of smooth muscle cells is inhibited, and intimal regeneration is effectively inhibited. The drug can be used as a new target for preventing and treating diseases such as vascular stenosis, stenosis after stent surgery, and stenosis after endarterectomy.

The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).

The invention discloses a sesquiterpene lactone derivative as well as preparation and application thereof in dialysis blood vessel protection. The sesquiterpene lactone derivative disclosed by the invention has a structure as shown in a formula (I), is mainly prepared from sesquiterpene lactone and amino acid through reaction, and can be used for preparing an internal arteriovenous fistula protection medicine for renal dialysis. Expression of PCNA and TLR4 in VSMCs can be effectively inhibited, proliferation of VSMCs in an AVF model is further inhibited, venous stenosis and thrombosis caused by neointimal hyperplasia are reduced, the incidence rate of AVF dysfunction is reduced, and the application prospect in preparation of internal arteriovenous fistula protection drugs for renal dialysis is good. # imgabs0 #